Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10368235 | 0.82 | LOXL2 (0.55) | AGXTLOXL2NPC1RAB9AKDM4E | |
| SCHEMBL6748905 | 0.77 | CYP2A6 (0.44) | AGXTLOXL2RAB9ANAMPTLMNA | |
| SCHEMBL7248298 | 0.74 | LOXL2 (0.53) | AGXTLOXL2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6751272 | 0.74 | ALDH1A1 (0.43) | NPC1RAB9ASMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL187684 | 0.73 | ALOX5 (0.51) | NPC1RAB9AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL7140949 | 0.73 | LOXL2 (0.56) | AGXTLOXL2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7030964 | 0.73 | MAOB (0.50) | AGXTLOXL2NPC1RAB9AKDM4E | |
| SCHEMBL22556182 | 0.73 | ALDH1A1 (0.47) | AGXTLOXL2KDM4EHPGDALDH1A1 | |
| SCHEMBL6750445 | 0.72 | BTN3A1 (0.33) | NPC1RAB9AL3MBTL1MAPTLMNA | |
| SCHEMBL8707442 | 0.71 | MAPT (0.52) | AGXTLOXL2NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044045-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN, INC. | 2004-03-04 | — | — | US | disclosed |
| US-6602900-B2 | F-type prostaglandins as ocular hypotensives | ALLERGAN, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020198249-A1 | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN SALES, INC. | 2002-12-26 | — | — | US | disclosed |
| US-6310087-B2 | TREATING GASTRIC OR DUODENAL ULCER, OSTEOPOROSIS, CONSTIPATION, RENAL DISORDERS, SEXUAL DYSFUNCTION, BALDNESS, DIABETES, CANCER AND DISORDER OF IMMUNE REGULATION | ALLERGAN SALES, INC. | 2001-10-30 | — | — | US | disclosed |
| US-20010016597-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | ALLERGAN SALES, INC. | 2001-08-23 | — | — | US | disclosed |
| EP-0825980-B1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLAKENYL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR HYPERTENSION | ALLERGAN SALES INC (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6204287-B1 | TREATING VISION DEFECTS | ALLERGAN SALES, INC. | 2001-03-20 | — | — | US | disclosed |
| US-6037364-A | ADMINISTERING OCULAR HYPOTENSIVE AGENT; TREATING CARDIOVASCULAR DISORDERS; ANTICOAGULANTS | ALLERGAN SALES, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| US-5972991-A | ADMINISTERING TO THE MAMMAL SUFFERING FROM OCULAR HYPERTENSION A F-TYPE PROSTAGLANDIN DERIVATIVE | ALLERGAN (US) | 1999-10-26 | — | — | US | disclosed |
| US-5834498-A | OCULAR HYPOTENSIVE AGENTS | ALLERGAN (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0825980-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLAKENYL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR HYPERTENSION | Allergan (US) | 1998-03-04 | — | — | EP | disclosed |
| WO-1996036599-A1 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR HYPERTENSION | ALLERGAN (US) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044045-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | PTGER1, PTGFR, PTGER2 | AGXT 3543/4885LOXL2 584/4885NPC1 3106/4885 |
| US-20010016597-A1 | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | PTGER1, PTGER2, PTGFR | AGXT 3091/4885LOXL2 502/4885NPC1 3691/4885 |
| US-20020198249-A1 | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents | PTGER1, PTGFR, PTGER2 | AGXT 3533/4885LOXL2 556/4885NPC1 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.